BMN-673 8R,9S

PARP inhibitor CAS# 1207456-00-5

BMN-673 8R,9S

Catalog No. BCC1422----Order now to get a substantial discount!

Product Name & Size Price Stock
BMN-673 8R,9S: 5mg $219 In Stock
BMN-673 8R,9S: 10mg Please Inquire In Stock
BMN-673 8R,9S: 20mg Please Inquire Please Inquire
BMN-673 8R,9S: 50mg Please Inquire Please Inquire
BMN-673 8R,9S: 100mg Please Inquire Please Inquire
BMN-673 8R,9S: 200mg Please Inquire Please Inquire
BMN-673 8R,9S: 500mg Please Inquire Please Inquire
BMN-673 8R,9S: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of BMN-673 8R,9S

Number of papers citing our products

Chemical structure

BMN-673 8R,9S

3D structure

Chemical Properties of BMN-673 8R,9S

Cas No. 1207456-00-5 SDF Download SDF
PubChem ID 44819242 Appearance Powder
Formula C19H14F2N6O M.Wt 380.35
Type of Compound N/A Storage Desiccate at -20°C
Synonyms Talazoparib (8R,9S); (8R,9S)-LT-673
Solubility DMSO : ≥ 50 mg/mL (131.46 mM)
H2O : < 0.1 mg/mL (insoluble)
*"≥" means soluble, but saturation unknown.
SMILES CN1C(=NC=N1)C2C(N=C3C=C(C=C4C3=C2NNC4=O)F)C5=CC=C(C=C5)F
Standard InChIKey IUEWAGVJRJORLA-HOTGVXAUSA-N
Standard InChI InChI=1S/C19H14F2N6O/c1-27-18(22-8-23-27)15-16(9-2-4-10(20)5-3-9)24-13-7-11(21)6-12-14(13)17(15)25-26-19(12)28/h2-8,15-16,25H,1H3,(H,26,28)/t15-,16-/m0/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of BMN-673 8R,9S

DescriptionBMN 673 is a novel PARP inhibitor with IC50 of 0.58 nM(PARP1). It does not inhibit PARG and is highly sensitive to PTEN mutation.
TargetsPARP    
IC500.58 nM    

BMN-673 8R,9S Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

BMN-673 8R,9S Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of BMN-673 8R,9S

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.6292 mL 13.1458 mL 26.2916 mL 52.5831 mL 65.7289 mL
5 mM 0.5258 mL 2.6292 mL 5.2583 mL 10.5166 mL 13.1458 mL
10 mM 0.2629 mL 1.3146 mL 2.6292 mL 5.2583 mL 6.5729 mL
50 mM 0.0526 mL 0.2629 mL 0.5258 mL 1.0517 mL 1.3146 mL
100 mM 0.0263 mL 0.1315 mL 0.2629 mL 0.5258 mL 0.6573 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on BMN-673 8R,9S

PARP1/2 inhibitors are a class of anticancer agents that target tumor-specific defects in DNA repair. BMN 673 is a highly potent PARP1/2 inhibitor.
In vitro: BMN 673 is a potent PARP1/2 inhibitor, but it does not inhibit other enzymes that we have tested. BMN673 exhibits selective antitumor cytotoxicity and elicits DNA repair biomarkers at much lower concentrations than earlier generation PARP1/2 inhibitors. BMN 673 targeted tumor cells with BRCA1, BRCA2, or PTEN gene defects selectively with 20- to more than 200-fold greater potency than existing PARP1/2 inhibitors in vitro [1].
In vivo: BMN 673 is readily orally bioavailable, with more than 40% absolute oral bioavailability in rats when dosed in CMC. Orally BMN 673 elicited remarkable antitumor activity in mice; xenografted tumors that carry defects in DNA repair due to BRCA mutations or PTEN deficiency were profoundly sensitive to oral BMN 673 treatment at well-tolerated doses. Synergistic antitumor effects were also found when BMN 673 was combined with temozolomide, SN38, or platinum drugs [1].
Clinical trial: Pharmacokinetics (PK), pharmacodynamics (PD), safety and anti-tumor activity of BMN 673 were evaluated in a 2-stage dose-escalation study with 3-6 patients (pts)/dose level. Results showed BMN 673 was well tolerated with impressive anti-tumor activity in pts with BRCA mut with a single agent recommended Phase II trial dose of 1000 μg/d due to dose-limiting thrombocytopenia.
Reference:
[1] Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, Wang B, Lord CJ, Post LE, Ashworth A. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res. 2013;19(18):5003-15.

Featured Products
New Products
 

Description

(8R,9S)-Talazoparib ((8R,9S)-BMN-673) is an enantiomer of Talazoparib, less active than Talazoparib on the inhibition of PARP1, with an IC50 of 144 nM.

Keywords:

BMN-673 8R,9S,1207456-00-5,Talazoparib (8R,9S); (8R,9S)-LT-673,Natural Products,PARP, buy BMN-673 8R,9S , BMN-673 8R,9S supplier , purchase BMN-673 8R,9S , BMN-673 8R,9S cost , BMN-673 8R,9S manufacturer , order BMN-673 8R,9S , high purity BMN-673 8R,9S

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: